Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: June 13, 2005
Last updated: March 17, 2010
Last verified: August 2006

RATIONALE: Giving drugs, such as docetaxel, directly into the pleura after surgery to drain the pleural effusion may help keep fluid from building up again.

PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of intrapleural docetaxel given after surgery in patients with malignant pleural effusion.

Condition Intervention Phase
Metastatic Cancer
Drug: docetaxel
Procedure: therapeutic thoracoscopy
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase I Trial of Intrapleural Docetaxel Administered Via an Implantable Catheter in Subjects With a Malignant Pleural Effusion

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Maximum tolerated dose by adverse event evaluation 1 month after treatment [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics by serum and pleural fluid analyses through 1 month [ Designated as safety issue: No ]
  • Clinical response by chest x-ray response and survival [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: July 2003
Detailed Description:



  • Determine the maximum tolerated dose of intrapleural docetaxel in patients with malignant pleural effusion.


  • Determine the toxicity profile of this drug in these patients.
  • Determine the pharmacokinetics of this drug in plasma and pleural fluid from these patients.
  • Determine the response in patients treated with this drug.

OUTLINE: This is a dose-escalation study.

Patients undergo thorascopic surgery to drain the malignant pleural effusion. An intrapleural catheter (Pleurx catheter) is then inserted for subsequent docetaxel instillation. Approximately 24 hours after surgery, patients receive docetaxel intrapleurally over 3 minutes via the Pleurx catheter. The Pleurx catheter is then clamped for 4 hours and the patient is placed in several different positions to ensure uniform distribution of docetaxel throughout the pleural cavity.

Cohorts of 3-6 patients receive escalating doses of intrapleural docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

After completion of study treatment, patients are followed at weeks 1 and 3 and then monthly thereafter.

PROJECTED ACCRUAL: Approximately 8-24 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed malignant pleural effusion (MPE)

    • Symptomatic disease
  • Candidate for thoracoscopic surgery for treatment of MPE

    • No known or suspected ipsilateral pleurodesis that would preclude surgery
  • No bilateral MPEs
  • No progressive extrapleural disease that is untreatable and/or resistant to systemic treatment



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 8.0 g/dL


  • ALT and/or AST ≤ 1.5 times upper limit of normal (ULN) (if alkaline phosphatase normal) OR
  • Alkaline phosphatase ≤ 2.5 times ULN (if ALT and/or AST normal)
  • Bilirubin normal
  • INR ≤ 1.5


  • Creatinine ≤ 1.8 mg/dL


  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment
  • No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • No peripheral neuropathy > grade 1


Biologic therapy

  • Not specified


  • No concurrent systemic chemotherapy

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00114205

United States, Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
National Cancer Institute (NCI)
Principal Investigator: David R. Jones, MD University of Virginia
  More Information

Additional Information:
No publications provided Identifier: NCT00114205     History of Changes
Other Study ID Numbers: CDR0000430930, UVACC-HIC-10722, UVACC-29303
Study First Received: June 13, 2005
Last Updated: March 17, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
malignant pleural effusion

Additional relevant MeSH terms:
Neoplasm Metastasis
Pleural Effusion
Pleural Effusion, Malignant
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Pleural Diseases
Pleural Neoplasms
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on December 01, 2015